BioCentury
ARTICLE | Financial News

Atara secures $38.5 million in series B

December 18, 2013 1:17 AM UTC

Atara Biotherapeutics Inc. (Brisbane, Calif.) secured $38.5 million in the initial close of a series B round. New investors Amgen Ventures; Celgene Corp. (NASDAQ:CELG); and EcoR1 Capital participated, along with existing investors Alexandria Venture Investments; DAG Ventures; Domain Associates; and Kleiner Perkins Caufield & Byers. Alexandria Venture's Joel Marcus joined Atara's board.

Amgen Inc. (NASDAQ:AMGN) and Kleiner Perkins launched Atara last year to develop six assets licensed from Amgen that the company said were "deprioritized programs." The products are housed in three daughter companies (see BioCentury Extra, Oct. 26, 2012). ...